What's in Neutec Ar-Ge San ve Tic A.Ş's pipeline?

Neutec Ar-Ge San ve Tic A.Ş has 8 drugs in our index: 4 marketed, 0 filed, 4 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Neutec Ar-Ge San ve Tic A.Ş's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Pfizer, Ain Shams Maternity Hospital, Baqiyatallah Medical Sciences University, Belarusian Medical Academy of Post-Graduate Education.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/neutec-ar-ge-san-ve-tic-a.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Neutec Ar-Ge San ve Tic A.Ş — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neutec Ar-Ge San ve Tic A.Ş pipeline: 4 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 4 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Salmeterol/Fluticasone Capsair®	Salmeterol/Fluticasone Capsair®	marketed	Long-acting beta-2 agonist/inhaled corticosteroid combination (LABA/ICS)	Beta-2 adrenergic receptor; glucocorticoid receptor	Respiratory/Pulmonology
Tiotropium/Formoterol	Tiotropium/Formoterol	marketed	Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor (tiotropium); Beta-2 adrenergic receptor (formoterol)	Respiratory/Pulmonology
Acetylcysteine/Doxofylline	Acetylcysteine/Doxofylline	marketed	Mucolytic/Bronchodilator combination		Respiratory/Pulmonology
Lansoprazole/Domperidone	Lansoprazole/Domperidone	marketed	Proton pump inhibitor + dopamine antagonist combination	H+/K+-ATPase (lansoprazole); dopamine D2/D3 receptors (domperidone)	Gastroenterology
Ipratropium + Levosalbutamol Free Dose Combination	Ipratropium + Levosalbutamol Free Dose Combination	phase 3	Combination bronchodilator (anticholinergic + beta-2 agonist)	Muscarinic acetylcholine receptors (M3) and beta-2 adrenergic receptor	Respiratory
Infex 400 MR	Infex 400 MR	phase 3	Macrolide antibiotic	50S ribosomal subunit	Infectious diseases
Ipratropium / Levosalbutamol Fixed Dose Combination	Ipratropium / Levosalbutamol Fixed Dose Combination	phase 3	Anticholinergic / Short-acting beta-2 agonist combination	Muscarinic acetylcholine receptors (ipratropium); Beta-2 adrenergic receptor (levosalbutamol)	Respiratory / Pulmonology
Infex 200 IR	Infex 200 IR	phase 3	carbapenem antibiotic	penicillin-binding proteins (PBPs)	Infectious diseases

Therapeutic area mix

Respiratory/Pulmonology · 3
Infectious diseases · 2
Gastroenterology · 1
Respiratory · 1
Respiratory / Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 2 shared drug classes
Pfizer · 2 shared drug classes
Ain Shams Maternity Hospital · 1 shared drug class
Baqiyatallah Medical Sciences University · 1 shared drug class
Belarusian Medical Academy of Post-Graduate Education · 1 shared drug class
Celltrion · 1 shared drug class
Centre Hospitalier Universitaire UCLouvain Namur · 1 shared drug class
AstraZeneca · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Neutec Ar-Ge San ve Tic A.Ş:

Cite this brief

Drug Landscape (2026). Neutec Ar-Ge San ve Tic A.Ş — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neutec-ar-ge-san-ve-tic-a. Accessed 2026-05-17.